middle.news
Neurizon Therapeutics Completes Fastest HEALEY ALS Trial Enrolment, Boosts Funding
2:58pm on Tuesday 25th of August, 2026 AEST
•
Biotechnology
Read Story
Neurizon Therapeutics Completes Fastest HEALEY ALS Trial Enrolment, Boosts Funding
2:58pm on Tuesday 25th of August, 2026 AEST
Key Points
Completed enrolment of 250 participants in HEALEY ALS Trial in under five months
Net loss narrowed to $10.7 million from $16.6 million in prior year
Secured five-year GMP supply agreement with Elanco Animal Health
Raised $20.8 million via equity and convertible notes, plus non-dilutive R&D financing
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE